泓友药业

Hongyou Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule precision medicines for oncology. The company focuses on targeting the RAS signaling pathway, which is a major driver in various aggressive cancers such as pancreatic, colorectal, and lung cancers. Their lead programs include highly selective inhibitors targeting specific KRAS mutations, including G12D and G12V, as well as upstream regulators like SOS1 and SHP2. By leveraging a deep understanding of structure-based drug design, Hongyou Pharmaceutical aims to provide next-generation therapies for patients with limited treatment options.